Atsena Therapeutics Reports Positive Gene Therapy Data at ARVO 2026
DURHAM, N.C., May 7, 2026 Atsena Therapeutics announced positive new clinical data from its investigational gene therapy programs ATSN-201...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
DURHAM, N.C., May 7, 2026 Atsena Therapeutics announced positive new clinical data from its investigational gene therapy programs ATSN-201...
RESEARCH TRIANGLE PARK, N.C., May 7, 2026 Opus Genetics announced new clinical and preclinical data presentations at the 2026...
